RT Journal Article
SR Electronic
T1 Seroprevalence of antibodies to SARS-CoV-2 is particularly high in patient population with ocular surface diseases
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.22.20198465
DO 10.1101/2020.09.22.20198465
A1 Shengjie Li
A1 Yichao Qiu
A1 Li Tang
A1 Zhujian Wang
A1 Wenjun Cao
A1 Xinghuai Sun
YR 2020
UL http://medrxiv.org/content/early/2020/11/19/2020.09.22.20198465.abstract
AB Coronavirus disease 2019 (COVID-19), a novel respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in December 2019. It is vitally important to perform a seroprevalence study to estimate the percentage of people with SARS-CoV-2 antibodies in the patient population with ocular surface diseases. IgG and IgM antibodies against the SARS-CoV-2 spike protein and nucleoprotein were measured using a commercially available magnetic chemiluminescence enzyme immunoassay kit. Throat swabs were tested for SARS-CoV-2 RNA in a designated virology laboratory. A total of 6, 414 individuals were enrolled. All participants throat swabs were RT-PCR-negative for SARS-CoV-2. Seroprevalence in the patient population was 0.31%. And the seroprevalevce in ocular surface diseases, no-ocular surface diseases and no-ocular diseases are 1.82% (6/330), 0.22% (10/4614) and 0.27% (4/1470) respectively.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Ethics Committees of Eye and ENT Hospital of Fudan University approved this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data supporting the conclusions of this article will be made available by the authors